Cetuximab sarotalocan
Cetuximab sarotalocan (RM-1929) is an IRdye700DX (near-infrared photosensitizing dye) conjugate of Cetuximab (anti-EGFR monoclonal antibody). Cetuximab sarotalocan can be used for head and neck cancers research.
For research use only. We do not sell to patients.
- CAS No.: 2166339-33-7
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All EGFR Isoforms
More
Biological Activity
EGFR
Cetuximab sarotalocan sodium is formed by an antibody-photosensitive complex that combines Cetuximab, an epidermal growth factor receptor monoclonal antibody, with the dye IRdye700DX, a photosensitive substance. After administration of Cetuximab sarotalocan sodium, only tumor cells are specifically destroyed by illumination with a red light at 690 nm[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2166339-33-7
-
SMILES
[Cetuximab sarotalocan]
-
Synonyms
RM-1929; Cetuximab-IRDye-700DX
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Go Omura, et al. Transnasal photoimmunotherapy with cetuximab sarotalocan sodium: Outcomes on the local recurrence of nasopharyngeal squamous cell carcinoma. Auris Nasus Larynx. 2022 Jun 29;S0385-8146(22)00167-5. [Content Brief]
[2]. Isaku Okamoto, et al. Quality-of-Life Evaluation of Patients with Unresectable Locally Advanced or Locally Recurrent Head and Neck Carcinoma Treated with Head and Neck Photoimmunotherapy. Cancers (Basel). 2022 Sep 11;14(18):4413. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Cetuximab sarotalocan Related Classifications
HY-P99500 Related Classifications
Powered by Bioz